CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
September 19 2018 - 4:08PM
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company
focused on developing transformative gene-based medicines for
serious diseases, today announced that it is commencing an
underwritten public offering of $200,000,000 of its common shares.
In addition, the underwriters will have a 30-day option to purchase
up to $30,000,000 of additional common shares at the public
offering price less the underwriting discount.
Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays
Capital Inc. and Wells Fargo Securities, LLC are acting as joint
book-running managers for the offering. Guggenheim Securities, LLC
and Needham & Company, LLC are acting as co-managers for the
offering. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the
offering.
An automatic shelf registration statement on Form S-3ASR
relating to these securities has been filed with the Securities and
Exchange Commission (SEC) and has become effective. This press
release shall not constitute an offer to sell or a solicitation of
an offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A copy
of the prospectus supplement relating to the offering will be filed
with the SEC and may be obtained, when available, from Goldman,
Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282,
Attention: Prospectus Department, by telephone at (866) 471-2526,
or by email at prospectus-ny@ny.email.gs.com; from Piper Jaffray
& Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@pjc.com; Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (888) 603-5847 or by email at
Barclaysprospectus@broadridge.com; or from Wells Fargo Securities,
LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York,
New York 10152, or by email at cmclientsupport@wellsfargo.com, or
by telephone at (800) 326-5897.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company
focused on developing transformative gene-based medicines for
serious diseases using its proprietary CRISPR/Cas9 gene-editing
platform. CRISPR Therapeutics AG is headquartered in
Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations
based in Cambridge, Massachusetts.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding CRISPR Therapeutics’ anticipated public offering. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, such as the intended offering terms, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on
Form 10-K for the year ended December 31, 2017, as filed with the
SEC on March 8, 2018, the prospectus supplement related to the
public offering and other filings that CRISPR Therapeutics may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent CRISPR Therapeutics’
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. CRISPR
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
CRISPR Investor Contact:Susan
Kim617-307-7503susan.kim@crisprtx.com
CRISPR Media Contact:Jennifer Paganelli WCG on behalf of CRISPR
347-658-8290jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024